Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 2

Conditions

Lymphoma 15Breast Neoplasms 13Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Glioblastoma 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Brain Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Leukemia 7Multiple Myeloma 6Hodgkin Disease 6Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, T-Cell, Cutaneous 5Lung Neoplasms 5Gliosarcoma 5Congenital Abnormalities 5Breast Neoplasms, Male 5Recurrence 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Immunoblastic Lymphadenopathy 4

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × Vorinostat × Clear all
NCT03713320 2022-04-08

SOLAR

miRagen Therapeutics, Inc.

Phase 2 Terminated
37 enrolled 23 charts
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00992446 2020-03-18

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
27 enrolled 13 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00810576 2012-08-07

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 3 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡